Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals: A Longitudinal Study

Background— HIV-infected individuals have an increased risk of myocardial infarction. Antiretroviral therapy (ART) is regarded as a major determinant of dyslipidemia in HIV-infected individuals. Previous genetic studies have been limited by the validity of the single-nucleotide polymorphisms (SNPs) interrogated and by cross-sectional design. Recent genome-wide association studies have reliably associated common SNPs to dyslipidemia in the general population. Methods and Results— We validated the contribution of 42 SNPs (33 identified in genome-wide association studies and 9 previously reported SNPs not included in genome-wide association study chips) and of longitudinally measured key nongenetic variables (ART, underlying conditions, sex, age, ethnicity, and HIV disease parameters) to dyslipidemia in 745 HIV-infected study participants (n=34 565 lipid measurements; median follow-up, 7.6 years). The relative impact of SNPs and ART to lipid variation in the study population and their cumulative influence on sustained dyslipidemia at the level of the individual were calculated. SNPs were associated with lipid changes consistent with genome-wide association study estimates. SNPs explained up to 7.6% (non–high-density lipoprotein cholesterol), 6.2% (high-density lipoprotein cholesterol), and 6.8% (triglycerides) of lipid variation; ART explained 3.9% (non–high-density lipoprotein cholesterol), 1.5% (high-density lipoprotein cholesterol), and 6.2% (triglycerides). An individual with the most dyslipidemic antiretroviral and genetic background had an ≈3- to 5-fold increased risk of sustained dyslipidemia compared with an individual with the least dyslipidemic therapy and genetic background. Conclusions— In the HIV-infected population treated with ART, the weight of the contribution of common SNPs and ART to dyslipidemia was similar. When selecting an ART regimen, genetic information should be considered in addition to the dyslipidemic effects of ART agents.

[1]  D. Strachan,et al.  LDL-cholesterol concentrations: a genome-wide association study , 2008, The Lancet.

[2]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[3]  Zucchini,et al.  An Introduction to Model Selection. , 2000, Journal of mathematical psychology.

[4]  J. Kao,et al.  Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Bernard Keavney,et al.  Association of apolipoprotein E genotypes with lipid levels and coronary risk. , 2007, JAMA.

[6]  J. Hoeg,et al.  Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[7]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[8]  D. Hayoz,et al.  High prevalence of peripheral arterial disease in HIV-infected persons. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  O. Kirk,et al.  Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? , 2004, The Journal of infectious diseases.

[10]  J. Beckmann,et al.  Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy , 2007, Pharmacogenetics and genomics.

[11]  J. Leonard,et al.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.

[12]  J. Ruidavets,et al.  An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients , 2001, AIDS.

[13]  S. Cole,et al.  Impact of HIV infection and HAART on serum lipids in men. , 2003, JAMA.

[14]  O. Kirk,et al.  Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study) , 2009, Circulation.

[15]  C. Hoggart,et al.  Genome-wide association analysis of metabolic traits in a birth cohort from a founder population , 2008, Nature Genetics.

[16]  O. Kirk,et al.  Class of antiretroviral drugs and the risk of myocardial infarction. , 2007, The New England journal of medicine.

[17]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[18]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[19]  K. Mossman.  The Wellcome Trust Case Control Consortium, U.K. , 2008 .

[20]  J. Dallongeville,et al.  Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. , 1992, Journal of lipid research.

[21]  R. Weber,et al.  Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study , 2005, Antiviral therapy.

[22]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[23]  P. Murtaugh,et al.  METHODS OF VARIABLE SELECTION IN REGRESSION MODELING , 1998 .

[24]  Christian Gieger,et al.  Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts , 2009, Nature Genetics.

[25]  M. McCarthy,et al.  Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes , 2008, Nature Genetics.

[26]  Marcia M. Nizzari,et al.  Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels , 2007, Science.

[27]  Teri A Manolio,et al.  Cohort studies and the genetics of complex disease , 2009, Nature Genetics.

[28]  C. Gieger,et al.  Genomewide association analysis of coronary artery disease. , 2007, The New England journal of medicine.

[29]  R. D'Agostino,et al.  Genotype score in addition to common risk factors for prediction of type 2 diabetes. , 2008, The New England journal of medicine.

[30]  D. Tregouet,et al.  Cholesterol gene polymorphisms and cardiovascular events. , 2008, The New England journal of medicine.

[31]  D. Podzamczer,et al.  Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. , 2003, The New England journal of medicine.

[32]  M. Egger,et al.  Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[34]  M. Schemper.  Predictive accuracy and explained variation , 2003, Statistics in medicine.

[35]  R. Collins,et al.  Common variants at 30 loci contribute to polygenic dyslipidemia , 2009, Nature Genetics.

[36]  Cholesterol gene polymorphisms and cardiovascular events. , 2008, The New England journal of medicine.

[37]  Hang Lee,et al.  Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. , 2007, The Journal of clinical endocrinology and metabolism.

[38]  M. Reilly,et al.  Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy , 2006, PLoS medicine.

[39]  M. Johnson,et al.  Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures , 2005, AIDS.

[40]  K. Narayan,et al.  Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2009, The New England journal of medicine.

[41]  R. Collins,et al.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.

[42]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[43]  Olle Melander,et al.  Polymorphisms associated with cholesterol and risk of cardiovascular events. , 2008, The New England journal of medicine.

[44]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[45]  C. Sabin,et al.  Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. , 2008, Circulation.

[46]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[47]  A. Lazzarin,et al.  Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. , 2005, AIDS.

[48]  Jonathan C. Cohen,et al.  Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. , 2002, Human molecular genetics.

[49]  J. Wang,et al.  Hypertriglyceridemia in the acquired immunodeficiency syndrome. , 1989, The American journal of medicine.

[50]  A. Telenti,et al.  Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. , 2005, The Journal of infectious diseases.

[51]  R. Xu.  Measuring explained variation in linear mixed effects models , 2003, Statistics in medicine.

[52]  J. Frohlich,et al.  APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease. , 2004, Atherosclerosis.

[53]  A. Telenti,et al.  Toxicogenetics of Antiretroviral Therapy: Genetic Factors that Contribute to Metabolic Complications , 2007, Antiviral therapy.